Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline demography and disease characteristics

From: Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

  Tofacitinib 5 mg BID Tofacitinib 10 mg BID Total
(n = 381) (n = 105) (n = 486)
Female, n (%) 318 (83.5) 86 (81.9) 404 (83.1)
Age in years, mean (SD) 53.5 (11.2) 49.3 (11.7) 52.6 (11.4)
Disease duration in years, mean (range) 7.8 (0.4–38.0) 6.1 (0.4–45.0) 7.4 (0.4–45.0)
Tender joint counta, n 16.1 17.0 16.3
Swollen joint counta, n 13.4 14.3 13.6
HAQ-DIb score 1.23 1.22 1.23
DAS28-4(ESR) score 6.0 6.1 6.0
DAS28-3(CRP) score 5.0 5.2 5.1
ESR, mm/h 50.7 47.7 50.1
CRP, mg/L 24.1 27.4 24.9
Concomitant methotrexate, n (%) 196 (51.4) 26 (24.8) 222 (45.7)
Concomitant systemic corticosteroids, n (%) 256 (67.2) 80 (76.2) 336 (69.1)
  1. Data are mean values except where indicated. Baseline values were those of the index study
  2. aScale 0–68 (tender/painful joints) and 0–66 (swollen joints); higher values indicate greater levels of disease activity
  3. bScale: 0–3; higher values indicate reduced physical function
  4. BID twice daily, CRP C-reactive protein, DAS Disease Activity Score, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, SD standard deviation